Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2027
GET FREE SAMPLE COPY @ https://www.marketresearchfuture.com/sample_request/1625
Schizophrenia: Increasing Prevalence of Mental Disorder is Expected to Moderate The Market Growth During The Forecast Period 2017-2023
Regional Analysis
The Americas dominate the global schizophrenia market owing to the presence of awareness of healthcare, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global schizophrenia market as result of increasing focus of various government agencies on the treatment of mental illness disease such as schizophrenia. Moreover, the growing public awareness about schizophrenia likely to boost the Europe market.
Asia Pacific is the fastest growing schizophrenia market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in India, Iran, Pakistan, Tanzania, over the forecasted period. Additionally, WHO initiative for training primary health-care personnel, providing access to essential drugs, and supporting families in providing home care lead the market growth of the schizophrenia in the region.
The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market.
Segmentation
The global schizophrenia market is segmented on the basis of by diagnosis, by treatment type, and by end user. On the basis of the diagnosis, it is segmented into blood and urine tests, brain imaging, vision testing, and others. On the basis of the treatment type, it is segmented into surgery, radiation therapy, medications, and others. On the basis of the end user, it is segmented into hospitals, clinics, diagnostic centers, rehabilitation centers and others.
Key Players
Some of key the players in the market are Minerva Neurosciences (U.S.), Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K)
Browse Full Report @ https://www.marketresearchfuture.com/reports/schizophrenia-market-1625
About us:
Market Research Future (MRFR) offers a variety of customers through cooking research reports (CRR), half-finished research reports (HCRR), raw research reports (3R), continuous feed research (CFR), market research & consulting services. Allows you to unravel the complexity of the industry.
inquiry:
Phone: +1 646 845 9312
